STAT China: A debut for CanSino Biologics and Cellular BioMed’s controversy
A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.
Hello and welcome back to STAT China. In this edition, Covid-19 vaccine updates, a privatization proposal draws a backlash, and the CEO of a newly formed biotech startup joins us on STAT Newsmaker.
Read Original Article: STAT China: A debut for CanSino Biologics and Cellular BioMed’s controversy »
